National Cancer Institute National Cancer Institute
U.S. National Institutes of Health National Cancer Institute
Search
NCI Home Cancer Topics Clinical Trials Cancer Statistics Research & Funding News About NCI
Ewing Family of Tumors Treatment (PDQ®)
Patient VersionHealth Professional VersionEn españolLast Modified: 03/26/2008



Purpose of This PDQ Summary






General Information






Cellular Classification






Stage Information






Treatment Option Overview






Ewing Tumor of Bone: Localized Tumors






Ewing Tumor of Bone: Metastatic Tumors






Ewing Tumor of Bone: Recurrent Tumors






Get More Information From NCI







Changes to This Summary (03/26/08)






More Information



Page Options
Print This Page  Print This Page
Print This Document  Print Entire Document
View Entire Document  View Entire Document
E-Mail This Document  E-Mail This Document
Quick Links
Director's Corner

Dictionary of Cancer Terms

NCI Drug Dictionary

Funding Opportunities

NCI Publications

Advisory Boards and Groups

NIH Calendar of Events

Español
NCI Highlights
New Study of Targeted Therapies for Breast Cancer

The Nation's Investment in Cancer Research FY 2009

President's Cancer Panel Annual Report: 2006-2007

Cancer Trends Progress Report: 2007 Update

Past Highlights
HPV Vaccines for Cervical Cancer
Changes to This Summary (03/26/08)

The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.

Purpose of This PDQ Summary

Added this new section.

General Information

This section was renamed from General Information About This PDQ Summary.

The subsection Origin and Incidence of Ewing Family of Tumors was renamed from General Information About Ewing Family of Tumors.

Added text to state that classic Ewing sarcoma, primitive neuroectodermal tumor, Askin tumor (chest wall), and extraosseous Ewing sarcoma are all derived from the same primordial stem cell.

Added Rodriguez-Galindo et al. as reference 9.

Added text to state that female gender and younger age predict for a good histologic response to preoperative therapy (cited Ferrari et al. as reference 23).

Ewing Tumor of Bone: Localized Tumors

Added text to state that for patients with residual disease following attempt at surgical resection, the IESS recommends 45 Gy to the original disease site plus a 10.8 Gy boost for patients with gross residual disease.

Back to TopBack to Top

< Previous Section  |  Next Section >


A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov